Chief Executive and Chief Scientific Officer
Nathalie Garçon, PharmD, PhD is currently the chief executive (CEO) and scientific officer (CSO) of BIOASTER. She joined BIOASTER, the French technology research institute for infectiology and microbiology as chief scientific officer in July 2014.In this role, Dr Garcon directs the scientific aspect of the institute with the objective of accelerating the access to new technologies in infectious diseases that patient can benefit from. She was promoted to CEO in April 2015.Following the successfulcompletion of two PhDs, one in biological pharmacy and the other in immunotoxicology and immunopharmacology, Dr Garçon moved to the UK for 1 year as a postdoctoral research fellow at the Royal Free Hospital in London, undertakingresearch on liposomes in vaccines. She then moved to the USA where she spent 4 years at Baylor College of Medicine in Houston, Texas, first as a postdoctoral research fellow, then as assistant professor, working on vaccine delivery systems and immunopotentiators. Dr Garçon joined SmithKline Beecham Biologicals now GlaxoSmithKline vaccines in 1990, where she set up and led the vaccine adjuvant and formulation group. She moved from this position, to head of technologies, head of research, vicepresident, head of global research and north America RD; and vice president, head of the global adjuvants and delivery systems centre for vaccines. In her last role within GSK vaccines before joining BIOASTER, Dr Garçon hold the position of vicepresident, head of adjuvants and technologies innovation centre, she provides leadership within GSK Biologicals in the fields of new vaccines technologies, from discovery to registration and commercialisation. Nathalie Garçon is Vice Presidentand Head of Global Adjuvant and technologies innovation centre at GSK vaccines Dr Garçon expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant, formulation and innovation technologies, analyticalmethods, pre-clinical experimentation and toxicology/safety evaluation, regulatory and licensure and testing. Dr Garçon is the 2014 laureate of the Stanley Plotkin award for vaccines and vaccine technologies. She has authored over 60 papers andbook chapters, is the editor of several books, and sit at the scientific committee of several journals. She holds more than 100 patents.
vaccine adjuvant, Vaccine delivery systems and immunopotentiators.